Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Collegium Pharmaceutical Inc before investing.

In this article, we go over a few key elements for understanding Collegium Pharmaceutical Inc’s stock price such as:

• Collegium Pharmaceutical Inc’s current stock price and volume
• Why Collegium Pharmaceutical Inc’s stock price changed recently
• Upgrades and downgrades for COLL from analysts
• COLL’s stock price momentum as measured by its relative strength

About Collegium Pharmaceutical Inc (COLL)

Before we jump into Collegium Pharmaceutical Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Want to learn more about Collegium Pharmaceutical Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc’s Stock Price as of Market Close

As of April 11, 2024, 4:00 PM, CST, Collegium Pharmaceutical Inc’s stock price was $36.39.

Collegium Pharmaceutical Inc is down 4.21% from its previous closing price of $37.99.

During the last market session, Collegium Pharmaceutical Inc’s stock traded between $37.95 and $38.89. Currently, there are 32.29 million shares of Collegium Pharmaceutical Inc stock available for purchase.

Collegium Pharmaceutical Inc’s price-earnings (P/E) ratio is currently at 43.1, which is high compared to the Pharmaceuticals industry median of 24.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Collegium Pharmaceutical Inc Stock Price History

Collegium Pharmaceutical Inc’s (COLL) price is currently down 6.26% so far this month.

During the month of April, Collegium Pharmaceutical Inc’s stock price has reached a high of $40.49 and a low of $35.72.

Over the last year, Collegium Pharmaceutical Inc has hit prices as high as $40.95 and as low as $20.83. Year to date, Collegium Pharmaceutical Inc’s stock is up 56.85%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Collegium Pharmaceutical Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 10, 2024, there was 1 analyst who downgraded Collegium Pharmaceutical Inc’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Collegium Pharmaceutical Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Collegium Pharmaceutical Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Collegium Pharmaceutical Inc’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Collegium Pharmaceutical Inc (COLL) by visiting AAII Stock Evaluator.

Relative Price Strength of Collegium Pharmaceutical Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 10, 2024, Collegium Pharmaceutical Inc has a weighted four-quarter relative price strength of 7.64%, which translates to a Momentum Score of 84 and is considered to be Very Strong.

Want to learn more about how Collegium Pharmaceutical Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Collegium Pharmaceutical Inc Stock Price: Bottom Line

As of April 11, 2024, Collegium Pharmaceutical Inc’s stock price is $36.39, which is down 4.21% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Collegium Pharmaceutical Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.